medigraphic.com

2024, Number 8

<< Back Next >>

Med Crit 2024; 38 (8)

Clinical efficacy of intravenous antihypertensive treatment with labetalol versus hydralazine in severe preeclampsia in obstetric intensive care unit

Ortega PAQ, Palacios PR, Téllez BGE, Jiménez CPM, Gaona VLS

Language: Spanish
References: 17
Page: 688-693
PDF size: 269.77 Kb.


ABSTRACT

Introduction: preeclampsia affects 7-10% of pregnancies and is associated with higher maternal and neonatal mortality rates; medical treatment is the control of blood pressure levels; labetalol is a non-selective competitive beta-blocker with blocking activity against postsynaptic alpha-1 receptors in vascular smooth muscles that causes vasodilation. Material and methods: randomized, open, parallel group, non-double-blind clinical trial in patients with severe preeclampsia. Results: 111 cases were included, 54 patients in the labetalol group and 57 in the hydralazine group. In the hydralazine group there were events of uterine atony (p = 0.016) and a higher incidence of bleeding > 500 mL (p = 0.094). At minute 40, similar outcomes were obtained between both groups with SBP values of 140 mmHg (p = 0.222), diastolic blood pressure (DBP) of 90 mmHg (p = 0.563) and mean arterial pressure (MAP) of 106 mmHg (p = 0.729); there was a higher percentage of neonates with Apgar < 8 at one minute in the hydralazine group (p = 0.067). Conclusions: the use of labetalol in patients with severe preeclampsia is equally effective as hydralazine at 40 minutes for hypertensive control, however, the time and number of doses was shorter in the labetalol group; there was less hospitalization of neonates in the labetalol group.


REFERENCES

  1. Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391-403.

  2. Sinkey RG, Battarbee AN, Bello NA, Ives CW, Oparil S, Tita ATN. Prevention, diagnosis, and management of hypertensive disorders of pregnancy: a comparison of international guidelines. Curr Hypertens Rep. 2020;22(9):66.

  3. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. Hypertensive disorders of pregnancy: isshp classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72(1):24-43.

  4. Dimitriadis E, Rolnik DL, Zhou W, Estrada-Gutierrez G, Koga K, Francisco RPV, et al. Pre-eclampsia. Nat Rev Dis Primers. 2023;9(1):8.

  5. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260.

  6. Awaludin A, Rahayu C, Daud NAA, Zakiyah N. Antihypertensive medications for severe hypertension in pregnancy: a systematic review and meta-analysis. Healthcare (Basel). 2022;10(2):325.

  7. Deng NJ, Xian-Yu CY, Han RZ, Huang CY, Ma YT, Li HJ, et al. Pharmaceutical administration for severe hypertension during pregnancy: Network meta-analysis. Front Pharmacol. 2023;13:1092501.

  8. Clark MA, Harvey RA, Finkel R, Rey JA, Whalen K. Pharmacology Lippincott's illustrated reviews. 5th ed. Lipincott, Williams & Wilkins, 2011.

  9. Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906-1916.

  10. Knowles HJ, Tian YM, Mole DR, Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res. 2004;95(2):162-169.

  11. Saugel B, Fletcher N, Gan TJ, Grocott MPW, Myles PS, Sessler DI; PeriOperative Quality Initiative XI (POQI XI) Workgroup Members. PeriOperative Quality Initiative (POQI) international consensus statement on perioperative arterial pressure management. Br J Anaesth. 2024;133(2):264-276.

  12. Miller J, McNaughton C, Joyce K, Binz S, Levy P. Hypertension management in emergency departments. Am J Hypertens. 2020;33(10):927-934.

  13. Kulkarni S, Glover M, Kapil V, Abrams SML, Partridge S, McCormack T, et al. Management of hypertensive crisis: British and Irish Hypertension Society Position document. J Hum Hypertens. 2023;37(10):863-879.

  14. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.

  15. S D, Novri DA, Hamidy Y, Savira M. Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial. F1000Res. 2023;11:1287.

  16. Mowafy SMS, Medhat MM. Evaluation of intravenous infusion of labetalol versus magnesium sulfate on cerebral hemodynamics of preeclampsia patients with severe features using transcranial doppler. J Clin Monit Comput. 2023;37(4):951-961.

  17. Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses. Hypertension. 2022;79(3):614-628.




2020     |     www.medigraphic.com